France-based inHEART provides AI-driven digital twin solutions for heart care. It focuses on visual cardiac intervention in patients with arrhythmias, transforming preoperative medical images into a 3D digital twin of the patient's heart.
The company claims the use of inHEART has shown a potential reduction in ventricular tachycardia (VT) procedure times by up to 60%. Moreover, image-guided ablations, facilitated by the inHEART solution, are reported to decrease VT recurrence rates by 38% compared to traditional ablation methods.
The technology enables cardiologists to optimize treatment strategies and improve clinical outcomes for patients with heart rhythm disorders. The company obtained its CE certification for the EU in May 2023 and subsequently received FDA approval in March 2024 .
Key Customers and Partnerships
In 2022, it achieved a milestone of performing 1,000 inHeart cases. The company’s first US customer was Hartford Healthcare in 2021 and first EU customer was AZ Sint-Jan in 2019.
Funding and Financials
In May 2024, the company secured USD 11 million in a funding round co-led by Vesalius Biocapital IV and Elaia Partners. The funds were allocated towards inHeart's commercial expansion and software development.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.